成本效果分析(CEA)对欧洲老年人流感疫苗接种政策的贡献
本综述描述了经济评价和真实世界证据(RWE)对欧洲老年人增强型流感疫苗评估的重要性。欧洲部分国家推荐为≥65岁人群接种增强型疫苗以减轻免疫衰老,部分国家免疫技术咨询组(NITAG)可能优先推荐特定增强型疫苗,在缺乏直接头对头疗效数据时需开展比较性经济评价并估计相对疫苗效力。不同的经济建模和成本效果分析(CEA)方法指导欧洲各国疫苗接种政策,RWE是CEA模型的重要证据来源。CEA在欧洲某些国家被视为疫苗评估的关键,但欧洲NITAG间经济评价(包括RWE使用)的进一步协调可能有益,同时需标准化疫苗评估方法。未来可能有更多国家将RWE作为CEA模型输入以支持NITAG对老年人增强型流感疫苗的推荐。
要点
- 欧洲部分国家推荐≥65岁人群接种增强型流感疫苗以减轻免疫衰老。
- 部分NITAG可能优先推荐特定增强型疫苗,需比较性经济评价和相对疫苗效力估计。
- RWE是CEA模型的重要证据来源,未来更多国家可能将其作为CEA输入。
核心结论
- CEA在欧洲某些国家被视为疫苗评估的关键,但欧洲NITAG间经济评价(包括RWE使用)的进一步协调可能有益,同时需标准化疫苗评估方法。
- 未来可能有更多国家将RWE作为CEA模型输入以支持NITAG对老年人增强型流感疫苗的推荐。
研究设计与样本
- 本综述描述了经济评价和真实世界证据(RWE)对欧洲老年人增强型流感疫苗评估的重要性。
主要发现
- ≥65岁人群面临严重流感结局风险增加,欧洲许多国家推荐该人群接种增强型疫苗以减轻免疫衰老。
- 部分NITAG可能优先推荐特定增强型疫苗,在缺乏直接头对头疗效数据时需开展比较性经济评价并估计增强型疫苗选项间的相对疫苗效力。
- 不同的经济建模和成本效果分析(CEA)方法指导欧洲各国疫苗接种政策,包括RWE等基础数据在这些模型中的使用方式。
- RWE是基于疾病因素(如抗原漂移和季节性变异)和实践因素(如开展多项随机临床试验以捕捉季节性变异的局限性;需要获得以患者为中心的真实世界终点如住院)的CEA模型输入的重要证据来源。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review describes the importance of economic evaluations and real-world evidence (RWE) for the assessment of enhanced influenza vaccines for older adults in Europe. Individuals ≥65 years of age are at increased risk of severe influenza outcomes and many countries in Europe recommend enhanced vaccines for this population to mitigate immunosenescence. Some National Immunization Technical Advisory Groups (NITAGs) may preferentially recommend a specific enhanced vaccine, necessitating comparative economic evaluation and estimation of relative vaccine effectiveness between enhanced vaccine options in the absence of direct head-to-head efficacy data. Distinct approaches to economic modeling and cost-effectiveness analysis (CEA) guide national vaccination policies in Europe, including how underlying data, such as RWE, are used in these models. RWE is an important evidence source for input into CEA models based on disease factors (e.g., antigenic shift and seasonal variation) and practical factors (e.g., limitations of performing multiple randomized clinical trials to capture seasonal variation; the need to obtain relevant patient-oriented, real-world endpoints, such as hospitalizations). CEA is considered crucial to vaccine assessment among certain countries in Europe, but further harmonization of economic evaluations, including the use of RWE, across NITAGs in Europe may be of benefit, alongside standardized approaches for vaccine appraisal. In the future, more countries may use RWE as an input in CEA models to support NITAG recommendations for enhanced influenza vaccines in older populations, especially considering the value of RWE for the assessment of influenza epidemiology and vaccine effectiveness as stated by the World Health Organization, and the availability of a broad RWE base for certain enhanced vaccines.
引用
- Chicoye A, Crépey P, Nguyen VH, et al. Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe. Vaccine. 2023. PMID: 37550142. doi:10.1016/j.vaccine.2023.07.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。